Vaxart, Inc. – Press Releases

Search

Year

March 14, 2024

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

Significant progress made in preparing for a Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator Topline data from Phase 1 norovirus study in lactating mothers expected in mid-2024 Steven Lo appointed President, Chief Executive Officer and

March 07, 2024

PDF Version

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. , March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2023 after the market close on Thursday, March

March 06, 2024

PDF Version

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

Michael J. Finney , Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif. , March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that it has appointed Steven Lo as President and Chief Executive Officer and a member

February 05, 2024

PDF Version

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

— Data served as foundation for current vaccine candidate for planned Phase 2 research — Vaxart vaccine candidates elicited strong antigen-specific serum IgG and IgA with neutralizing activity against multiple variants of concern — Vaccination reduced SARS-CoV-2 shedding following infectious

January 19, 2024

PDF Version

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator - - Project NextGen is a $5 billion initiative by the U.S. Department of Health and Human Services to develop innovative vaccines and therapeutics

January 16, 2024

PDF Version

Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management

SOUTH SAN FRANCISCO, Calif. , Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615 shares of its common stock in a registered direct offering at an offering

January 16, 2024

PDF Version

Vaxart, Inc. Announces Management Change

Chief Executive Officer Andrei Floroiu Resigns Chair Michael J. Finney , Ph.D. to Serve as Interim Chief Executive Officer SOUTH SAN FRANCISCO, Calif. , Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced a change in management.

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Press Releases.

Search